BioSpace News Archive

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced a partnership with actress, singer-songwriter and advocate Lynda Carter Altman to accelerate diagnostics and treatments, including precision medicine approaches, for a deadly and difficult-to-treat form of blood cancer.

The European Patent Office has announced to approve Bioretec Oy’s hybrid composite material patent application EP3782657A1 and will grant and publish the patent after the Company’s confirmation.

Cancer is rapidly becoming a global concern. According to 2015 report by the American Cancer Society, 1 in 8 deaths globally is due to cancer.

Advent of insulin is key event in the history of diabetes treatment.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved DAXXIFY™ (DaxibotulinumtoxinA-lanm) for injection for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, PhD, will be among the featured speakers at the 3rd Annual Gene Therapy for Ophthalmic Disorders conference.

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced it has appointed Michael R. Bishop, M.D., F.A.C.P., F.A.S.C.O., to its Scientific Advisory Board (SAB).

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs, today announced that it will be participating in the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14, 2022.

Annovis Bio, Inc., a late-stage clinical drug platform company addressing neurodegenerative diseases, released the following letter to stockholders from its Chief Executive Officer Dr. Maria Maccecchini.

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company will deliver a corporate presentation at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.